Literature DB >> 33830292

Dynamic contrast-enhanced magnetic resonance lymphangiography.

Karen I Ramirez-Suarez1, Luis O Tierradentro-Garcia2, Christopher L Smith3, Ganesh Krishnamurthy2, Fernando A Escobar2, Hansel J Otero2, Jordan B Rapp2, Yoav Dori3, David M Biko2.   

Abstract

Lymphatic flow disorders include a broad spectrum of abnormalities that can originate in the lymphatic or the venous system. The development of these disorders is multifactorial and is most commonly associated with congenital heart diseases and palliative surgeries that these patients undergo. Central lymphatic disorders might be secondary to traumatic leaks, lymphatic overproduction, conduction abnormalities or lymphedema, and they can progress to perfusion anomalies. Several imaging modalities have been used to visualize the lymphatic system. However, the imaging of central lymphatic flow has always been challenging. Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL) allows for visualization of central lymphatic flow disorders and has been recently applied for the assessment of plastic bronchitis, protein-losing enteropathy, chylothorax and chylopericardium, among other lymphatic disorders. The hepatic and mesenteric accesses are innovative and promising techniques for better identification and understanding of these abnormalities. The main objectives of this review are to discuss the physiology and anatomy of the lymphatic system and review the current uses of DCMRL in the diagnosis and management of lymphatic flow disorders.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Children; Contrast-enhanced; Dynamic imaging; Lymphangiography; Lymphatic flow; Lymphatic system; Magnetic resonance imaging

Mesh:

Substances:

Year:  2021        PMID: 33830292     DOI: 10.1007/s00247-021-05051-6

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  3 in total

Review 1.  Noncontrast Magnetic Resonance Lymphography.

Authors:  Lionel Arrivé; Sarah Derhy; Sanaâ El Mouhadi; Laurence Monnier-Cholley; Yves Menu; Corinne Becker
Journal:  J Reconstr Microsurg       Date:  2015-03-31       Impact factor: 2.873

2.  Management of chylothorax and chylopericardium in pediatric patients: experiences at Siriraj Hospital, Bangkok.

Authors:  Narumon S Densupsoontorn; Pipop Jirapinyo; Renu Wongarn; Nuchnoi Thamonsiri; Apichart Nana; Duangmanee Laohaprasitiporn; Jarupim Soongswang; Kritvikrom D Durongpisitkul; Samphant A Pornvilawan
Journal:  Asia Pac J Clin Nutr       Date:  2005       Impact factor: 1.662

Review 3.  Pediatric pulmonary lymphatic flow Disorders: Diagnosis and management.

Authors:  David M Biko; Yoav Dori; Melanie Savoca; Ganesh Krishnamurthy; Christopher L Smith; Pablo Laje; Jonathan J Rome; Fernando Escobar
Journal:  Paediatr Respir Rev       Date:  2019-11-29       Impact factor: 2.726

  3 in total
  4 in total

Review 1.  Lymphatic anomalies in congenital heart disease.

Authors:  Karen I Ramirez-Suarez; Luis Octavio Tierradentro-García; David M Biko; Hansel J Otero; Ammie M White; Yoav Dori; Christopher L Smith; Seth Vatsky; Jordan B Rapp
Journal:  Pediatr Radiol       Date:  2022-07-16

2.  Plastic bronchitis secondary to bocavirus in a previously healthy 4-year-old with negative lymphatic evaluation.

Authors:  Cynara Leon; Katharine Tsukahara; Kaitlyn Boggs; Pelton Phinizy
Journal:  Pediatr Pulmonol       Date:  2022-06-06

3.  Serial T2-Weighted Thoracic and Abdominal Lymphatic Imaging in Fontan Patients-New Insights into Dynamics of Lymphatic Abnormalities after Total Cavopulmonary Connection.

Authors:  Julia Moosmann; Christian Schroeder; Oliver Rompel; Ariawan Purbojo; Sven Dittrich
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-29

4.  Plastic Bronchitis-A Serious Rare Complication Affecting Children Only after Fontan Procedure?

Authors:  Ilona Pałyga-Bysiecka; Aneta Maria Polewczyk; Maciej Polewczyk; Elżbieta Kołodziej; Henryk Mazurek; Andrzej Pogorzelski
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.